BIOMARIN PHARMACEUTICAL INC Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 133.00 thousand shares for the 3-month period ending 2014-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2014-09-30 was 133.00K shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2013-09-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month |
|---|---|---|
| 2014-09-30 | 133.00K shares 10-Q · filed 2015-11-02 | 0.00 shares 10-Q · filed 2014-10-28 |
| 2013-09-30 | 0.00 shares 10-Q · filed 2014-10-28 | 0.00 shares 10-Q · filed 2014-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |